Why Packaging Cost Is Only Part Of The Equation
When evaluating pharmaceutical cold chains, packaging is often one of the first costs organisations consider.
However, packaging typically represents only a fraction of the total cost of transporting temperature-sensitive medicines.
A more useful approach is to consider the total cost of ownership (TCO), which includes every activity and resource required to move products safely from manufacturing to the patient.
These costs include:
- Transportation
- Refrigerated infrastructure
- Operational management
- Product loss
- Inventory
- Regulatory compliance
- Supply chain disruption
Optimising packaging alone may reduce procurement costs, but it does not necessarily reduce the overall cost of operating the cold chain.
The Biggest Drivers Of Cold Chain Costs
1. Transportation
Transportation is often the largest single cost in pharmaceutical logistics.
Depending on the shipment, this may include:
- Air freight
- Temperature-controlled trucking
- Premium freight services
- Last-mile distribution
- Expedited shipments
When delays occur, transportation costs can increase rapidly through rerouting, premium capacity, or emergency shipments.
2. Temperature-Controlled Infrastructure
Maintaining a cold chain often requires significant infrastructure across the shipment journey.
This may include:
- Refrigerated warehouses
- Airport cold rooms
- Temperature-controlled vehicles
- Backup refrigeration systems
- Temporary cold storage
These assets help reduce risk but also increase operating costs, energy consumption, and operational complexity.
3. Operational Complexity
One of the most overlooked cost drivers is the complexity of managing pharmaceutical supply chains.
Every additional handover, supplier, and transfer point requires:
- Planning
- Coordination
- Monitoring
- Documentation
- Communication
As supply chains become more global, these operational costs continue to grow.
4. Temperature Excursions And Product Loss
A single temperature excursion can have significant financial consequences.
Potential costs include:
- Product replacement
- Quality investigations
- Product quarantine
- Regulatory reporting
- Shipment delays
- Lost patient supply
For high-value biologics and specialty medicines, preventing even a small number of excursions can have a substantial impact on overall supply chain cost.
5. Inventory And Working Capital
Cold chain performance also affects inventory strategy.
When organisations lack confidence in supply chain performance, they may hold larger safety stocks to reduce the risk of shortages.
This ties up working capital and increases storage requirements.
More reliable logistics networks can help companies optimise inventory levels while maintaining supply continuity.
6. Sustainability And Energy Consumption
Environmental performance is becoming an increasingly important cost consideration.
Cold chain infrastructure requires significant energy to operate, while emissions reporting and sustainability targets are becoming more prominent across the pharmaceutical industry.
Reducing unnecessary refrigerated infrastructure and avoiding product loss can help lower both environmental impact and long-term operating costs.
7. Supply Chain Disruption
Global pharmaceutical supply chains operate in an increasingly unpredictable environment.
Disruption may result from:
- Airport congestion
- Severe weather
- Customs delays
- Geopolitical events
- Capacity constraints
Every disruption has a financial impact, whether through delayed deliveries, additional handling, emergency transport, or increased operational effort.
Visible Costs Vs Hidden Costs
Many pharmaceutical organisations focus on visible costs such as packaging or freight rates because they are easy to measure.
However, hidden costs often have a much greater impact on the overall economics of the supply chain.
| Visible Costs |
Hidden Costs |
| Packaging |
Product loss |
| Freight charges |
Temperature excursions |
| Storage fees |
Quality investigations |
| Container leasing |
Operational complexity |
| Handling charges |
Emergency shipments |
| Customs fees |
Inventory carrying costs |
| Fuel surcharges |
Delayed patient access |
Reducing hidden costs often delivers greater long-term value than reducing the cost of individual logistics components.
Why Total Cost Of Ownership Matters
Two cold chain solutions may have very different purchase prices while producing similar, or even lower, total operating costs.
For example, a higher-performance packaging solution may help reduce:
- Temperature-controlled trucking requirements
- Cold storage dependency
- Product loss
- Emergency interventions
- Supply chain disruption
When viewed across the entire shipment lifecycle, these operational savings may outweigh differences in packaging cost.
This is why many pharmaceutical companies increasingly evaluate cold chain solutions using total cost of ownership rather than procurement price alone.
How SkyCell Helps Reduce Total Cold Chain Costs
SkyCell's approach focuses on reducing the operational costs that sit behind pharmaceutical logistics rather than simply optimising container performance.
By combining:
- Long-runtime hybrid containers
- Real-time shipment visibility
- Lane intelligence through Validaide
- Coordinated intervention capability
pharmaceutical companies can better understand where risk exists and deploy resources more efficiently.
This can help reduce:
- Dependence on refrigerated infrastructure
- Emergency shipments
- Product loss from temperature excursions
- Operational complexity
- Carbon emissions
Rather than lowering costs by reducing protection, the objective is to improve decision-making so protection is applied where it delivers the greatest value.
Why This Matters As Pharmaceutical Supply Chains Evolve
Pharmaceutical supply chains are becoming more complex.
Biologics, cell and gene therapies, specialty medicines, and increasingly global distribution networks all place greater pressure on logistics operations.
At the same time, organisations face:
- Rising transportation costs
- Greater sustainability expectations
- Increased regulatory scrutiny
- More frequent operational disruption
These trends are encouraging pharmaceutical companies to look beyond individual logistics costs and focus on improving the efficiency of the entire cold chain.
What This Means For Pharmaceutical Companies
Reducing cold chain costs is not about choosing the lowest-cost packaging or transport provider.
It is about understanding where costs are created across the supply chain and identifying opportunities to improve resilience, simplify operations, and reduce unnecessary infrastructure.
Organisations that combine:
- Risk-aware planning
- Real-time visibility
- Operational flexibility
- Resilient temperature protection
are increasingly able to improve both cost efficiency and supply chain performance.
Summary
- Packaging is only one component of pharmaceutical cold chain cost
- The largest cost drivers include transportation, infrastructure, operational complexity, product loss, inventory, sustainability, and disruption
- Hidden costs often have a greater financial impact than visible logistics costs
- Total cost of ownership provides a more accurate way to evaluate cold chain solutions
- Reducing uncertainty helps pharmaceutical companies deploy infrastructure more efficiently
- SkyCell combines long-runtime hybrid containers, visibility, lane intelligence through Validaide, and coordinated intervention to help reduce total cold chain operating costs
